An Update on SARS-CoV-2 Clinical Trial Results—What We Can Learn for the Next Pandemic

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors

This review is a good summary of the current knowledge of SARS-CoV-2 drugs. However, this reviewer has several comments to improve the manuscript.

 

Table1

Aren’t the receptors for HCoV-OC43 and HCoV-HKU “9-O-acetylated sialic acid”? (Fung & Liu, Annu Rev Microbiol. 2019. PMID: 31226023)

 

Abbreviations

There are many abbreviations, so it would be better to put a separate list of abbreviations. There are also many abbreviations that are not defined (e.g. SM inhibitor).

 

Clinical Trial Table

This reviewer thinks the authors should add period and country/region information of the clinical trial in the Clinical Trial Tables. This is because it gives us a clue as to what variants were prevalent during the clinical trial.

 

Minor Comments

Page 15, line 200: “EBV” is an abbreviation that appears only once and is generally Epstein-Barr Virus. Therefore, it should be removed.

Page 28, line 482: SARS-CoV-2 is spelled incorrectly.

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 2 Report

Comments and Suggestions for Authors

The article describes in great detail the recent and relevant information about COVID-19. For a better understanding of the article and the extensive information, it is suggested that you add 2 images, one that encompasses Host-targeting antivirals and another with immunomodulatory drugs.

Author Response

Please see the attachment

Author Response File: Author Response.pdf